Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;8(Suppl 6):S569-S572.
doi: 10.21037/tcr.2019.05.25.

Revisiting anti-angiogenic therapy for recurrent glioblastoma

Katherine B Peters  1
Affiliations
Editorial

Revisiting anti-angiogenic therapy for recurrent glioblastoma

Katherine B Peters. Transl Cancer Res. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.05.25). The author has no conflicts of interest to declare.

Comment on

References

    1. Johnson DR, Omuro AMP, Ravelo A, et al. Overall survival in patients with glioblastoma before and after bevacizumab approval. Curr Med Res Opin 2018;34:813-20. 10.1080/03007995.2017.1392294 - DOI - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. 10.1056/NEJMoa043330 - DOI - PubMed
    1. Wick W, Gorlia T, Bendszus M, et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 2017;377:1954-63. 10.1056/NEJMoa1707358 - DOI - PubMed
    1. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40. 10.1200/JCO.2008.19.8721 - DOI - PubMed
    1. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943-53. 10.1016/S1470-2045(14)70314-6 - DOI - PubMed